N-Acetylcysteine (NAC) is a glutathione precursor and glutamatergic modulator that addresses two key features of ASD pathophysiology: oxidative stress and excitatory-inhibitory imbalance. A pilot RCT demonstrated large effect sizes for irritability reduction.
Mechanism#
Glutathione restoration: NAC is the rate-limiting precursor for glutathione (GSH) synthesis; GSH is consistently depleted in ASD.
Toxic metal chelation support: Restored GSH facilitates conjugation and excretion of mercury (Hg), lead (Pb), and cadmium (Cd)—metals that displace essential cofactors (Primitive 3: mis-metallation).
Glutamate modulation: NAC activates the cystine-glutamate antiporter, reducing synaptic glutamate and restoring excitatory-inhibitory balance.
Clinical Evidence#
Pilot RCT (n=33, 12 weeks): NAC significantly improved the Aberrant Behavior Checklist (ABC) irritability subscale with a large effect size (d=0.96, P<0.01). Well-tolerated with mild GI side effects.
Clinical Considerations#
Dose range in studies: 900-2700 mg/day in divided doses. GI side effects (nausea, loose stools) are the most common complaint. May be combined with other ASD interventions targeting the microbiome.
Cross-References#
Article network
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Deepen metal/concept entities + 8 new sources for T1D/schizophrenia
WikiBiome Deploy Bot · +57 −0
Inspect exact Git diff ↗